Aberdeen Group plc Acquires 79,265 Shares of Fulcrum Therapeutics, Inc. $FULC

Aberdeen Group plc boosted its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 135.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 137,961 shares of the company’s stock after purchasing an additional 79,265 shares during the period. Aberdeen Group plc owned about 0.25% of Fulcrum Therapeutics worth $1,269,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Farther Finance Advisors LLC lifted its position in shares of Fulcrum Therapeutics by 108.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock worth $65,000 after buying an additional 3,697 shares during the period. Russell Investments Group Ltd. raised its stake in Fulcrum Therapeutics by 4,209.3% during the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after acquiring an additional 9,092 shares in the last quarter. Assetmark Inc. acquired a new position in Fulcrum Therapeutics during the third quarter worth $88,000. Y Intercept Hong Kong Ltd bought a new position in shares of Fulcrum Therapeutics during the third quarter valued at $104,000. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of Fulcrum Therapeutics by 26.1% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company’s stock valued at $89,000 after purchasing an additional 2,677 shares in the last quarter. 89.83% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Robert J. Gould sold 15,000 shares of Fulcrum Therapeutics stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total transaction of $178,050.00. Following the completion of the sale, the director owned 469,864 shares in the company, valued at $5,577,285.68. The trade was a 3.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the sale, the insider owned 6,053,960 shares of the company’s stock, valued at $84,634,360.80. The trade was a 40.82% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.00% of the stock is currently owned by company insiders.

Fulcrum Therapeutics Stock Down 6.2%

Shares of FULC opened at $11.00 on Friday. The stock’s fifty day simple moving average is $10.91 and its 200-day simple moving average is $9.42. The firm has a market capitalization of $595.32 million, a PE ratio of -9.32 and a beta of 3.19. Fulcrum Therapeutics, Inc. has a 12-month low of $2.32 and a 12-month high of $15.74.

Analysts Set New Price Targets

FULC has been the subject of a number of recent analyst reports. The Goldman Sachs Group reiterated a “positive” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Truist Financial upped their price objective on shares of Fulcrum Therapeutics from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. JPMorgan Chase & Co. assumed coverage on shares of Fulcrum Therapeutics in a report on Monday, January 12th. They set an “overweight” rating and a $20.00 price objective for the company. Piper Sandler reiterated an “overweight” rating and issued a $23.00 target price (up previously from $16.00) on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Finally, HC Wainwright increased their price target on Fulcrum Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Fulcrum Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $19.11.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.